Energy & climate · Pipeline & development
Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026
Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be presented as an oral presentation on November 14 at 3:45 p.m. EST Data expand on clinically...
Original source
Read the source — prnewswire.com ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.